37188537|t|Association of APOE4, Osteoarthritis, beta-Amyloid, and Tau Accumulation in Primary Motor and Somatosensory Regions in Alzheimer Disease.
37188537|a|BACKGROUND AND OBJECTIVES: One of the most prevalent chronic diseases, osteoarthritis, may work in conjunction with apolipoprotein E-epsilon4 (APOE-epsilon4) to accelerate Alzheimer's disease (AD) alterations, particularly in the primary motor (precentral) and somatosensory (postcentral) cortices. To understand the reasoning behind this, we investigated how osteoarthritis and APOE-epsilon4 influence the accumulation of beta-amyloid (Abeta) and tau accumulation in primary motor and somatosensory regions in Abeta-positive (Abeta+) elderly adults. METHODS: We selected Abeta+ Alzheimer's Disease Neuroimaging Initiative participants, defined by baseline 18F-florbetapir (FBP) Abeta PET standard uptake value ratio (SUVR) of AD summary cortical regions, who had longitudinal Abeta PET, the records of osteoarthritis medical history and APOE-epsilon4 genotyping. We examined how osteoarthritis and APOE-epsilon4 relate to baseline and longitudinal Abeta accumulation, tau deposition measured at follow-up in precentral and postcentral cortical areas, and how they modulate Abeta-associated future higher tau levels, adjusting for age, sex, and diagnosis and employing multiple comparisons correction. RESULTS: 374 individuals (mean age 75, 49.2% female, 62.8% APOE-epsilon4 carrier) underwent longitudinal FBP PET with a median follow-up of 3.3 years (interquartile range (IQR) 3.4, range 1.6~9.4) were analyzed, and 96 people had 18F-flortaucipir (FTP) tau PET measured at a median of 5.4 (IQR 1.9, range 4.0~9.3) years post-baseline FBP PET. Neither osteoarthritis nor APOE-epsilon4 was related to baseline FBP SUVR in precentral and postcentral regions. At follow-up, osteoarthritis rather than APOE-epsilon4 was associated with faster Abeta accumulation in postcentral (beta=0.005[95% ci, 0.001, 0.008]) over time. In addition, osteoarthritis but not the APOE-epsilon4 allele was strongly linked to higher follow-up FTP tau levels in precentral (beta=0.098[95% ci, 0.034, 0.162]) and postcentral (beta=0.105[95% ci, 0.040, 0.169]) cortices. OA and APOE-epsilon4 were also interactively associated with higher follow-up FTP tau deposition in precentral (beta=0.128[95% ci, 0.030, 0.226]) and postcentral (beta=0.124[95% ci, 0.027, 0.223]) regions. DISCUSSION: This study suggests that OA was associated with faster Abeta accumulation and higher Abeta-dependent future tau deposition in primary motor and somatosensory regions, providing novel insights into how OA increases the risk of AD. GLOSSARY: Abeta: beta-amyloid; AD: Alzheimer's disease; CU: cognitively unimpaired; CI: cognitively impaired; MCI: mild cognitive impairment; OA: osteoarthritis; FBP: 18F-florbetapir; FTP: 18F-flortaucipir; PET: Positron emission tomography; SUVR: Standard uptake value ratio.
37188537	15	20	APOE4	Gene	348
37188537	22	36	Osteoarthritis	Disease	MESH:D010003
37188537	56	59	Tau	Gene	4137
37188537	119	136	Alzheimer Disease	Disease	MESH:D000544
37188537	209	223	osteoarthritis	Disease	MESH:D010003
37188537	254	279	apolipoprotein E-epsilon4	Gene	348
37188537	310	329	Alzheimer's disease	Disease	MESH:D000544
37188537	331	333	AD	Disease	MESH:D000544
37188537	498	512	osteoarthritis	Disease	MESH:D010003
37188537	575	580	Abeta	Gene	351
37188537	586	589	tau	Gene	4137
37188537	649	654	Abeta	Gene	351
37188537	665	670	Abeta	Gene	351
37188537	710	715	Abeta	Gene	351
37188537	717	736	Alzheimer's Disease	Disease	MESH:D000544
37188537	795	810	18F-florbetapir	Chemical	MESH:C545186
37188537	812	815	FBP	Chemical	MESH:C545186
37188537	817	822	Abeta	Gene	351
37188537	865	867	AD	Disease	MESH:D000544
37188537	915	920	Abeta	Gene	351
37188537	941	955	osteoarthritis	Disease	MESH:D010003
37188537	1018	1032	osteoarthritis	Disease	MESH:D010003
37188537	1087	1092	Abeta	Gene	351
37188537	1107	1110	tau	Gene	4137
37188537	1212	1217	Abeta	Gene	351
37188537	1243	1246	tau	Gene	4137
37188537	1445	1448	FBP	Chemical	MESH:C545186
37188537	1570	1586	18F-flortaucipir	Chemical	MESH:C000591008
37188537	1593	1596	tau	Gene	4137
37188537	1674	1677	FBP	Chemical	MESH:C545186
37188537	1691	1705	osteoarthritis	Disease	MESH:D010003
37188537	1748	1751	FBP	Chemical	MESH:C545186
37188537	1810	1824	osteoarthritis	Disease	MESH:D010003
37188537	1878	1883	Abeta	Gene	351
37188537	1971	1985	osteoarthritis	Disease	MESH:D010003
37188537	2184	2186	OA	Disease	MESH:D010003
37188537	2427	2429	OA	Disease	MESH:D010003
37188537	2457	2462	Abeta	Gene	351
37188537	2487	2492	Abeta	Gene	351
37188537	2510	2513	tau	Gene	4137
37188537	2603	2605	OA	Disease	MESH:D010003
37188537	2628	2630	AD	Disease	MESH:D000544
37188537	2642	2647	Abeta	Gene	351
37188537	2663	2665	AD	Disease	MESH:D000544
37188537	2667	2686	Alzheimer's disease	Disease	MESH:D000544
37188537	2688	2690	CU	Disease	
37188537	2716	2718	CI	Disease	
37188537	2732	2740	impaired	Disease	MESH:D060825
37188537	2742	2745	MCI	Disease	
37188537	2752	2772	cognitive impairment	Disease	MESH:D003072
37188537	2774	2776	OA	Disease	MESH:D010003
37188537	2778	2792	osteoarthritis	Disease	MESH:D010003
37188537	2794	2797	FBP	Chemical	MESH:C545186
37188537	2799	2814	18F-florbetapir	Chemical	MESH:C545186
37188537	2821	2837	18F-flortaucipir	Chemical	MESH:C000591008
37188537	Association	MESH:C545186	MESH:D000544
37188537	Association	MESH:D010003	348
37188537	Association	MESH:D000544	348
37188537	Association	MESH:C545186	351
37188537	Association	351	4137
37188537	Association	MESH:D003072	351
37188537	Association	MESH:D000544	4137
37188537	Association	MESH:D000544	351
37188537	Association	MESH:D010003	351

